0%
Print report
Variant interpretation report

PTEN c.147del, p.Asn49LysfsTer5

NM_000314.8:c.147del NP_000305.3:p.(Asn49LysfsTer5) Frameshift · exon 2 View identifiers
Classification
Likely pathogenic

Variant description:

The PTEN NM_000314.8:c.147del (NP_000305.3:p.(Asn49LysfsTer5)) frameshift variant has not previously been reported in somatic cancers (COSMIC). This variant is predicted to result in an absent or disrupted protein product. Based on available guidelines, this variant is considered to be Likely Pathogenic.

Five-step scale from benign to pathogenic. This variant is likely pathogenic. Select a step to read what it means.

Likely pathogenic.A likely pathogenic classification under the recorded framework.

In plain language

Gene-level background from the recorded interpretation.

About PTEN

PTEN is a tumor suppressor gene that encodes a phosphatase converting the lipid messenger PIP3 back to PIP2 at the cell membrane, thereby restraining the AKT/mTOR signaling pathway that drives cell growth, proliferation, and survival. It is one of the most frequently mutated genes across many types of human cancer, and its loss promotes unchecked cell growth, survival, and genomic instability, partly through impaired DNA repair. Germline loss-of-function variants in PTEN cause Cowden syndrome, an inherited cancer predisposition disorder associated with elevated risk of breast and thyroid cancer.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen PTEN VCEP v3.2. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 2 Benign evidence criteria: 0
Pathogenic criteria applied · 2
PVS1Very strong
PVS1 · very strong

Met at very strong: c.147 frameshift is far 5' of PTEN p.D375 (c.1121) in the biologically relevant NM_000314.8 transcript.

PM2Supporting
PM2 · supporting

Met at supporting strength: the variant was absent from gnomAD v2.1 and v4.1, satisfying the VCEP PM2 population-absence requirement below 0.00001 allele frequency.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Likely pathogenic

Likely Pathogenic: PVS1 (very strong) plus PM2 (supporting) satisfy the PTEN Expert Panel's Rule20.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

SpliceAI score
0.287 maximum delta

Recorded SpliceAI maximum delta score: 0.287. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied SpliceAI ↗
ClinVar submissions
1 reported laboratory submissions

1 Likely pathogenic.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen PTEN VCEP v3.2, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 2 not met · 10 not assessed · 14 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

Among the requested consequence/LoF criteria, PVS1 is met at very strong strength under the PTEN-specific decision tree; PM4 and BP3 are not applicable under their VCEP rules.

No literature source was needed to adjudicate these three criteria.

The variant is NM_000314.8:c.147del, a coding frameshift predicted to produce NP_000305.3:p.(Asn49LysfsTer5).

The PTEN VCEP's PP3 and BP4 computational pathways are limited to synonymous/intronic splice situations or missense REVEL situations, and BP7 is limited to synonymous/intronic variants at or beyond +7/-21.

Accordingly, PP3, BP4, and BP7 are all not applicable before predictor scores are considered.

Met · 2

PVS1 Very strongVCEPMet at very strong: c.147 frameshift is far 5' of PTEN p.D375 (c.1121) in the biologically relevant NM_000314.8 transcript. Details ▾Hide ▴
Reasoning

NM_000314.8:c.147del (NP_000305.3:p.(Asn49LysfsTer5), p.(N49Kfs*5)) is a frameshift in exon 2. The PTEN VCEP decision tree states that a nonsense or frameshift variant predicted to undergo NMD, with the stop codon or disruption at or 5' to p.D375 (c.1121), and with the exon present in biologically relevant transcript NM_000314.8, receives PVS1. This variant disrupts the transcript at c.147, well 5' of c.1121, and exon 2 is present in NM_000314.8; therefore PVS1 is met at full strength, reported as very strong.

VCEP rule
Nonsense or frameshift | Predicted to undergo NMD: stop codon or disruption at or 5' to p.D375 (c.1121) -> exon is present in biologically-relevant transcript NM_000314.8 | PVS1
Evidence considered
  • Variant assessment: NM_000314.8:c.147del; NP_000305.3:p.(Asn49LysfsTer5) / p.(N49Kfs*5); frameshift; exon 2.
  • PVS1_DecisionTree_PTEN.pdf, page 1, nonsense or frameshift row: a variant predicted to undergo NMD with disruption at or 5' to p.D375 (c.1121), in an exon present in biologically relevant transcript NM_000314.8, is assigned PVS1.
  • The variant is at c.147, which is 5' of the governing c.1121 threshold; no downgrade rule applies.
Still missing
  • No variant-specific pre-assigned row for c.147del, p.Asn49LysfsTer5, or p.N49Kfs*5 was found when PVS1_DecisionTree_PTEN.pdf.txt was searched; the applicable decision-tree path was used.
Sources
PM2 SupportingVCEPMet at supporting strength: the variant was absent from gnomAD v2.1 and v4.1, satisfying the VCEP PM2 population-absence requirement below 0.00001 allele frequency. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP PM2 rule applies at supporting strength when the variant is absent in population databases or has allele frequency <0.00001 (0.001%) in gnomAD or another large sequenced population; if multiple alleles are present in a subpopulation, that subpopulation frequency must be <0.00002 (0.002%). NM_000314.8:c.147del was absent from the default all-comers gnomAD v2.1 and gnomAD v4.1 records. The VCEP rule does not specify a non-cancer or exome-only population source, so the default all-comers records were used.

VCEP rule
Absent in population ... Databases present at <0.00001 (0.001%) allele frequency in gnomAD or another large sequenced population. If multiple alleles are present within any subpopulation, allele frequency in that subpopulation must be <0.00002 (0.002%).
Evidence considered
  • gnomAD v2.1 record for NM_000314.8:c.147del: absent; source_data empty, corresponding to no reported allele frequency.
  • gnomAD v4.1 record for NM_000314.8:c.147del: absent; source_data empty, corresponding to no reported allele frequency.
  • Population-source selection: the PTEN VCEP PM2 rule names gnomAD or another large sequenced population but does not require a non-cancer or exome-only subset; therefore the default all-comers gnomAD records were used.
Sources

Not met · 2 · evaluated, threshold not reached

BA1 VCEPNot met: the variant was absent from gnomAD v2.1 and v4.1, rather than exceeding the VCEP BA1 threshold of >0.00056 allele frequency. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP BA1 threshold is gnomAD Filtering allele frequency >0.00056 (0.056%). NM_000314.8:c.147del was absent from gnomAD v2.1 and gnomAD v4.1, so no allele frequency exceeding the BA1 threshold is present.

VCEP rule
gnomAD Filtering allele frequency >0.00056 (0.056%)
Evidence considered
  • gnomAD v2.1 record for NM_000314.8:c.147del: absent; source_data empty, so no filtering allele frequency was reported.
  • gnomAD v4.1 record for NM_000314.8:c.147del: absent; source_data empty, so no filtering allele frequency was reported.
Sources
BS1 VCEPNot met: the variant was absent from gnomAD v2.1 and v4.1, with no allele frequency in either VCEP BS1 range of 0.0000043–0.00056. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP BS1 ranges require a gnomAD Filtering allele frequency from 0.000043 (0.0043%) up to 0.00056 (0.056%) for strong evidence, or from 0.0000043 (0.00043%) up to 0.000043 (0.0043%) for supporting evidence. NM_000314.8:c.147del was absent from gnomAD v2.1 and gnomAD v4.1, so no frequency in either BS1 range was observed.

VCEP rule
gnomAD Filtering allele frequency from 0.000043 (0.0043%) up to 0.00056 (0.056%) ... Allele frequency from 0.0000043 (0.00043%) up to 0.000043 (0.0043%).
Evidence considered
  • gnomAD v2.1 record for NM_000314.8:c.147del: absent; source_data empty, so no filtering allele frequency was reported.
  • gnomAD v4.1 record for NM_000314.8:c.147del: absent; source_data empty, so no filtering allele frequency was reported.
Sources

Not assessed · 10 · no assessment recorded

PS2 VCEPNot assessed: no proband-level de novo observation, parental testing, maternity or paternity confirmation, or family-history information is available. Details ▾Hide ▴
Reasoning

The available case evidence does not report a proband with confirmed or presumed de novo occurrence, parental genotypes, maternity or paternity confirmation, or absence of family history. Therefore, the PTEN VCEP PS2 rule cannot be evaluated.

Evidence considered
  • No proband-level de novo, parental-testing, maternity/paternity-confirmation, or family-history evidence is present in the available case materials.
Still missing
  • Proband-level de novo status is not documented.
  • Parental genotypes and maternity/paternity confirmation are not documented.
  • Family history is not documented.
Sources
PS3 VCEPNot assessed: mmc2 Table S2 contains no matching row for this frameshift, so the VCEP's ≤ -1.11 phosphatase threshold cannot be evaluated. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP permits PS3 for damaging functional studies, including PS3_Moderate when phosphatase activity is ≤ -1.11 per Mighell et al. 2018. The governing mmc2 Table S2 is a missense-variant saturation assay, and searches for c.147del, p.Asn49LysfsTer5, and p.N49Kfs*5 found no matching row or pre-assigned code. This variant is a frameshift, and no separate VCEP-governed damaging functional assay result for it is available in the reviewed evidence. Therefore PS3 cannot be assessed from the available evidence without substituting an unapproved rule or extrapolating from other variants.

VCEP rule
Well-established _in vitro_ or _in vivo_ functional studies supportive of a damaging effect on the gene or gene product. * Phosphatase activity ≤ -1.11 per Mighell et al. 2018, PMID: 29706350.
Evidence considered
  • ClinGen PTEN VCEP v3.2 PS3 rule: PS3_Moderate is based on phosphatase activity ≤ -1.11 per Mighell et al. 2018 (PMID:29706350).
  • mmc2.xlsx, Table S2: searches for c.147del, p.Asn49LysfsTer5, and p.N49Kfs*5 returned no matching row; the table is explicitly the missense saturation-mutagenesis assay table and contains no pre-assigned code for this frameshift.
  • Case normalization identifies NM_000314.8:c.147del as NP_000305.3:p.(Asn49LysfsTer5), a frameshift; no separate VCEP-governed variant-specific damaging functional assay result was available in the reviewed evidence.
Still missing
  • No entry for c.147del, p.Asn49LysfsTer5, or p.N49Kfs*5 was found in the VCEP-governing file mmc2.xlsx converted text; a variant-specific validated damaging functional assay result would be needed.
Sources
PS4 VCEPNot assessed: no PTEN phenotype-specificity score or case-control counts, odds ratio, confidence interval, or p-value are available for c.147del. Details ▾Hide ▴
Reasoning

The PTEN VCEP permits PS4 from either phenotype-specificity scores or a sufficiently powered case-control study. The available case record provides no Cleveland Clinic or pediatric phenotype scores, affected-proband count, unaffected-control count, odds ratio, confidence interval, p-value, or other case-control data for NM_000314.8:c.147del. The literature packet contains no AI-classified PS4 papers, and the only extracted full-text paper (PMID:26467025) does not mention c.147del or provide PTEN-specific case observations, phenotype data, or population comparisons. Therefore the VCEP rule cannot be evaluated; PS4 is not assessed.

VCEP rule
Probands with specificity score 4-15.5 (see text) OR The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls.
Evidence considered
  • ClinGen PTEN VCEP specification v3.2, PS4 instructions: a sufficiently powered case-control study may qualify when odds ratio >2 for a PHTS component phenotype, p<0.05, and the 95% confidence-interval lower limit >1.5; alternatively, phenotype-specificity scores are summed across independent probands.
  • literature_pass.json: ai_classified_papers is empty and no PS4 paper was screened as variant-specific.
  • PMID:26467025 paper_extracts.json: the paper does not mention PTEN c.147del / p.(N49Kfs*5) and reports no PTEN-specific case observations, phenotype data, segregation data, or population frequency for this variant.
Still missing
  • Obtain independent-proband Cleveland Clinic or pediatric phenotype scores, or a sufficiently powered affected-versus-control study reporting counts or an odds ratio with 95% confidence interval and p-value.
Sources
PM6 VCEPNot assessed: no presumed de novo observation with disease and no family history is documented for this variant. Details ▾Hide ▴
Reasoning

The available case evidence does not report any presumed de novo observation in a patient with disease and no family history, nor does it provide parental testing or phenotype-specific proband details. Therefore, the PTEN VCEP PM6 rule cannot be evaluated.

Evidence considered
  • No proband-level presumed de novo observation, disease phenotype, family-history assessment, or parental-testing result is present in the available case materials.
Still missing
  • Presumed de novo proband observation is not documented.
  • Disease phenotype and phenotype specificity are not documented.
  • Family history and parental testing are not documented.
Sources
PP1 VCEPNot assessed: no affected relatives, variant-status results, cosegregation observations, or meiosis count are documented. Details ▾Hide ▴
Reasoning

The available case evidence contains no affected family members with variant-status information and no segregation observations or meiosis count. Therefore, the PTEN VCEP PP1 rule cannot be evaluated at supporting, moderate, or strong strength.

Evidence considered
  • No family segregation data, affected-relative genotypes, or informative meioses are present in the available case materials.
Still missing
  • Affected-family-member observations are not documented.
  • Variant status in affected relatives is not documented.
  • The number of informative meioses is not documented.
Sources
BS2 VCEPNot assessed: gnomAD reports no variant record but provides no homozygote observation or healthy-individual clinical status required by the VCEP BS2 rule. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP BS2 rule requires an observation in the homozygous state in a healthy or PHTS-unaffected individual, with the specified observation-count conditions. The available gnomAD records report the variant as absent and provide no homozygote count or individual-level healthy/PHTS-unaffected observation, so BS2 cannot be evaluated.

VCEP rule
Observed in the homozygous state in a healthy or PHTS-unaffected individual. One observation if homozygous status confirmed, two if not confirmed. To be applied at supporting evidence level if BS1 is also applied. ... Two homozygous observations with no clinical data provided, or meets criteria for BS2 but BS1 is also applied.
Evidence considered
  • gnomAD v2.1 and v4.1 both report the variant as absent and contain empty source_data; neither provides a homozygote count or clinical status for a homozygous individual.
Still missing
  • A confirmed homozygous observation in a healthy or PHTS-unaffected individual, or the VCEP-specified unconfirmed-observation count, is unavailable.
Sources
BS3 VCEPNot assessed: mmc2 Table S2 contains no matching row for this frameshift, so the VCEP's >0 phosphatase threshold cannot be evaluated. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP permits BS3_Supporting for a functional study showing no damaging effect, including phosphatase activity >0 per Mighell et al. 2018. The governing mmc2 Table S2 is a missense-variant saturation assay, and searches for c.147del, p.Asn49LysfsTer5, and p.N49Kfs*5 found no matching row or pre-assigned code. This variant is a frameshift, and no separate VCEP-governed benign functional assay result for it is available in the reviewed evidence. Therefore BS3 cannot be assessed without extrapolating from unrelated variants or applying a non-VCEP rule.

VCEP rule
_In vitro_ or _in vivo_ functional study or studies showing no damaging effect on protein function. * Phosphatase activity >0 per Mighell et al. 2018, PMID: 29706350.
Evidence considered
  • ClinGen PTEN VCEP v3.2 BS3 rule: BS3_Supporting may use phosphatase activity >0 per Mighell et al. 2018 (PMID:29706350).
  • mmc2.xlsx, Table S2: searches for c.147del, p.Asn49LysfsTer5, and p.N49Kfs*5 returned no matching row; the table is explicitly the missense saturation-mutagenesis assay table and contains no pre-assigned code for this frameshift.
  • Case normalization identifies NM_000314.8:c.147del as NP_000305.3:p.(Asn49LysfsTer5), a frameshift; no separate VCEP-governed variant-specific benign functional assay result was available in the reviewed evidence.
Still missing
  • No entry for c.147del, p.Asn49LysfsTer5, or p.N49Kfs*5 was found in the VCEP-governing file mmc2.xlsx converted text; a variant-specific validated benign functional assay result would be needed.
Sources
BS4 VCEPNot assessed: no affected relatives lacking the variant or family-level non-segregation observations are documented. Details ▾Hide ▴
Reasoning

The available case evidence does not report affected relatives who lack the variant, the number of families with non-segregation, or phenotype and testing details sufficient to distinguish non-segregation from phenocopy or another molecular cause. Therefore, the PTEN VCEP BS4 rule cannot be evaluated.

Evidence considered
  • No affected-relative genotype/phenotype discordance, family count, or alternative-cause assessment is present in the available case materials.
Still missing
  • Affected relatives without the variant are not documented.
  • The number of families showing lack of segregation is not documented.
  • Phenotype and alternative molecular-cause information for potentially discordant relatives is not documented.
Sources
BP2 VCEPNot assessed: no qualifying trans observation or three cis/phase-unknown observations with different pathogenic PTEN variants are documented. Details ▾Hide ▴
Reasoning

The PTEN Expert Panel permits BP2 at supporting strength when the variant is observed in trans with a pathogenic or likely pathogenic PTEN variant, or when there are at least three observations in cis and/or phase unknown with different pathogenic or likely pathogenic PTEN variants. The available case evidence contains no documented affected-proband observation, second PTEN variant, phase assignment, or qualifying three-observation series for NM_000314.8:c.147del. The criterion therefore cannot be evaluated.

VCEP rule
Observed in trans with a pathogenic or likely pathogenic PTEN variant OR at least three observations in cis and/or phase unknown with different pathogenic/likely pathogenic PTEN variants.
Evidence considered
  • ClinGen PTEN Expert Panel specification v3.2, BP2 supporting rule: "Observed in trans with a pathogenic or likely pathogenic PTEN variant OR at least three observations in cis and/or phase unknown with different pathogenic/likely pathogenic PTEN variants."
  • Case evidence review: no affected-proband co-occurrence, second PTEN variant, phase assignment, or qualifying three-observation series was reported for NM_000314.8:c.147del.
Still missing
  • Documented co-occurrence of NM_000314.8:c.147del with a different pathogenic or likely pathogenic PTEN variant
  • Phase information establishing trans, or at least three qualifying cis/phase-unknown observations
Sources
BP5 VCEPNot assessed: no two qualifying cases with an alternate highly penetrant disorder and non-overlapping PTEN history are documented. Details ▾Hide ▴
Reasoning

The PTEN VCEP requires at least two cases in which the variant is found with an alternate molecular basis, with the other disorder highly penetrant and the patient's personal or family history showing no overlap with PTEN. The available evidence contains no such cases, alternate-gene diagnosis, penetrance assessment, or non-overlapping history. Absence of these data does not establish that no qualifying cases exist, so BP5 is not assessed.

VCEP rule
At least two such cases are required for criteria to apply. In addition, the other gene/disorder must be considered highly penetrant AND the patient’s personal/family history must demonstrate no overlap between the other gene and PTEN.
Evidence considered
  • ClinGen PTEN VCEP specification v3.2, BP5 instructions require at least two cases, a highly penetrant alternate gene/disorder, and personal/family history demonstrating no overlap between the alternate disorder and PTEN.
  • The case evidence and reviewed literature provide no alternate molecular diagnosis, qualifying case series, penetrance evidence, or non-overlapping personal/family history for c.147del.
Still missing
  • Obtain at least two documented cases with the variant and an alternate molecular diagnosis, including evidence of high penetrance and no phenotype overlap with PTEN.
Sources
Not applicable · 14· recorded as not applicable Show reasons ▾Hide reasons ▴
PS1 N/ANot applicable: c.147del produces p.(Asn49LysfsTer5), a frameshift rather than a same-amino-acid missense change. Details ▾Hide ▴
Reasoning

PS1 is not applicable because the queried variant is the frameshift NM_000314.8:c.147del, p.(Asn49LysfsTer5), rather than a missense substitution producing a same-amino-acid change. No rule-conforming same-amino-acid comparison can therefore be made.

VCEP rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change OR different variant at same nucleotide position as a pathogenic splicing variant, where in silico models predict impact equal to or greater than the known pathogenic variant.
Evidence considered
  • Case variant: NM_000314.8:c.147del, predicted protein consequence p.(Asn49LysfsTer5), a frameshift.
Sources
PM1 N/ANot applicable: residue 49 is outside all VCEP-defined catalytic motifs, which are limited to residues 90-94, 123-130, and 166-168. Details ▾Hide ▴
Reasoning

PM1 is not applicable because the variant affects residue 49, while the PTEN VCEP defines its critical functional-domain route as catalytic motifs at residues 90-94, 123-130, and 166-168 (NP_000305.3). The case evidence also reports no statistically significant hotspot, and the VCEP rule does not name a somatic hotspot source that would provide an alternative route.

VCEP rule
Located in a mutational hot spot and/or critical and well-established functional domain. Defined to include residues in catalytic motifs: 90-94, 123-130, 166-168 (NP_ 000305.3)
Evidence considered
  • PTEN VCEP PM1 definition: catalytic motifs at residues 90-94, 123-130, and 166-168 (NP_000305.3); the variant consequence is p.(Asn49LysfsTer5), beginning at residue 49.
  • Cancer Hotspots search reported no statistically significant hotspot for PTEN N49; the VCEP PM1 rule does not name Cancer Hotspots, COSMIC, or another somatic hotspot source as an applicable route.
Sources
PM3 VCEPNot applicable: the PTEN Expert Panel explicitly designates PM3 as not applicable to PTEN. Details ▾Hide ▴
Reasoning

The ClinGen PTEN Expert Panel specifies that PM3 is not applicable to PTEN. Therefore, no recessive-disease trans-phase assessment is performed for NM_000314.8:c.147del.

VCEP rule
This rule is not applicable to PTEN.
Evidence considered
  • ClinGen PTEN Expert Panel specification v3.2, PM3 entry: "Not Applicable"; the accompanying PTEN-specific instruction states, "This rule is not applicable to PTEN."
Sources
PM4 N/ANot applicable: PM4 covers in-frame indels or stop-loss variants, whereas c.147del is a frameshift. Details ▾Hide ▴
Reasoning

The PTEN VCEP limits PM4 to protein length changes caused by in-frame deletions or insertions in a non-repeat region, or to stop-loss variants, including in-frame changes affecting a catalytic motif and protein extensions. This variant is a frameshift and is neither an in-frame insertion/deletion nor a stop-loss variant, so PM4 is not applicable.

VCEP rule
Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants. Applies to in-frame insertions or deletions impacting at least one residue in a catalytic motif (see PM1), and variants causing protein extension.
Evidence considered
  • Variant assessment: NM_000314.8:c.147del is classified as a frameshift producing p.(Asn49LysfsTer5), not an in-frame indel or stop-loss change.
  • The PTEN VCEP PM4 rule specifies protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants.
Sources
cspec ↗pvs1_variant_assessment
PM5 N/ANot applicable: PM5 requires a missense change, but c.147del produces the frameshift p.(Asn49LysfsTer5). Details ▾Hide ▴
Reasoning

PM5 is not applicable because the governing PTEN rule requires a missense change at an amino acid residue, whereas NM_000314.8:c.147del is a frameshift producing p.(Asn49LysfsTer5).

VCEP rule
Missense change at an amino acid residue where a different missense change determined to be pathogenic or likely pathogenic has been seen before. In addition, variant being interrogated must have BLOSUM62 score equal to or less than the known variant.
Evidence considered
  • Case variant: NM_000314.8:c.147del, predicted protein consequence p.(Asn49LysfsTer5), classified as a frameshift.
Sources
PP2 N/ANot applicable: PP2 is limited to missense variants, whereas c.147del produces the frameshift p.(Asn49LysfsTer5). Details ▾Hide ▴
Reasoning

PP2 is not applicable because the governing PTEN rule is explicitly limited to a missense variant, while NM_000314.8:c.147del is a frameshift producing p.(Asn49LysfsTer5).

VCEP rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • Case variant: NM_000314.8:c.147del, predicted protein consequence p.(Asn49LysfsTer5), a frameshift.
Sources
PP3 N/ANot applicable: PTEN PP3 covers synonymous/intronic splice predictions or missense REVEL >0.7, whereas c.147del is a frameshift variant. Details ▾Hide ▴
Reasoning

The PTEN VCEP PP3 rule scopes the splicing pathway to synonymous or intronic variants and the protein-impact pathway to missense variants with REVEL score > 0.7. NM_000314.8:c.147del is a frameshift variant, p.(Asn49LysfsTer5), so it lies outside every PP3 pathway. The available SpliceAI result is not used because the governing PP3 rule does not name frameshift variants as an applicable situation.

VCEP rule
To be applied to synonymous or intronic variants where SpliceAl and VarSeak _in silico_ models predict a splicing impact (SpliceAl: scores 0.5-1 are consider evidence of pathogenic. VarSeak: Class 4 and 5 are consider evidence of pathogenic). May also be applied to missense variants with REVEL score > 0.7.
Evidence considered
  • ClinGen PTEN VCEP PP3 specification: ‘To be applied to synonymous or intronic variants where SpliceAl and VarSeak _in silico_ models predict a splicing impact (SpliceAl: scores 0.5-1 are consider evidence of pathogenic. VarSeak: Class 4 and 5 are consider evidence of pathogenic). May also be applied to missense variants with REVEL score > 0.7.’
  • Variant NM_000314.8:c.147del produces NP_000305.3:p.(Asn49LysfsTer5) and is classified in the case facts as a frameshift, not a synonymous, intronic, or missense variant; therefore no PP3 pathway applies.
Sources
PP4 VCEPNot applicable: the PTEN VCEP incorporates phenotype specificity into PS4 Use 2 and explicitly excludes independent PP4 application. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP explicitly marks PP4 as not applicable and states that phenotype specificity has been incorporated into PS4 Use 2; PP4 must therefore not be applied independently.

VCEP rule
PTEN EP Commentary: Phenotype specificity has been incorporated into the rule specifications for PS4 Use 2.
Evidence considered
  • ClinGen PTEN VCEP specification v3.2, PP4 entry: applicability is Not applicable; the commentary states that phenotype specificity has been incorporated into PS4 Use 2.
Sources
PP5 VCEPNot applicable: the PTEN VCEP explicitly states that PP5 is not for use. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP marks PP5 not applicable for this VCEP and states that the criterion is not for use; no PP5 evidence can be applied under the governing framework.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ClinGen PTEN VCEP specification v3.2, PP5 entry: applicability is Not Applicable for this VCEP.
Sources
BP1 VCEPNot applicable: the PTEN VCEP explicitly marks BP1 as Not Applicable. Details ▾Hide ▴
Reasoning

The PTEN VCEP marks BP1 as Not Applicable.

VCEP rule
Not Applicable
Evidence considered
  • PTEN VCEP CSPEC entry for BP1 explicitly states applicability: Not Applicable.
Sources
BP3 VCEPNot applicable: the PTEN VCEP explicitly marks BP3 as not applicable in its Version 3.2 criteria. Details ▾Hide ▴
Reasoning

The PTEN VCEP marks BP3 as Not Applicable. BP3 therefore cannot be assigned to this variant under the governing VCEP framework.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen PTEN VCEP Version 3.2 CSPEC entry for BP3: applicability is Not Applicable.
Sources
BP4 N/ANot applicable: PTEN BP4 covers synonymous/intronic splice predictions or missense REVEL <0.5, while c.147del is a frameshift with a truncating protein effect. Details ▾Hide ▴
Reasoning

The PTEN VCEP BP4 rule scopes the splicing pathway to synonymous or intronic variants with concordant SpliceAl and VarSeak predictions of no splicing impact, and separately allows missense variants with REVEL score < 0.5. NM_000314.8:c.147del is a frameshift variant, p.(Asn49LysfsTer5), outside both pathways. BP4 is therefore not applicable; a no-impact splice prediction cannot negate the truncating protein effect.

VCEP rule
To be applied to synonymous or intronic variants where SpliceAl and VarSeak _in silico_ models predict no splicing impact (SpliceAl: scores 0-0.2 are considered evidence of benign. VarSeak: Class 1 and 2 are considered evidence of benign). Not to be applied for variants which may impact the intron 1 splice donor or acceptor sites, and to be used cautiously for variants which may impact the intron 6 splice acceptor. May also be applied to missense variants with REVEL score \< 0.5.
Evidence considered
  • ClinGen PTEN VCEP BP4 specification: ‘To be applied to synonymous or intronic variants where SpliceAl and VarSeak _in silico_ models predict no splicing impact (SpliceAl: scores 0-0.2 are considered evidence of benign. VarSeak: Class 1 and 2 are considered evidence of benign). Not to be applied for variants which may impact the intron 1 splice donor or acceptor sites, and to be used cautiously for variants which may impact the intron 6 splice acceptor. May also be applied to missense variants with REVEL score < 0.5.’
  • Variant NM_000314.8:c.147del produces NP_000305.3:p.(Asn49LysfsTer5) and is classified in the case facts as a frameshift, outside the synonymous/intronic and missense BP4 pathways; any SpliceAI result is not evidence for BP4 in this situation.
Sources
BP6 VCEPNot applicable: the PTEN VCEP explicitly states that BP6 is not for use. Details ▾Hide ▴
Reasoning

The ClinGen PTEN VCEP marks BP6 not applicable for this VCEP and states that the criterion is not for use; a reputable-source benign assertion cannot be applied under this framework.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ClinGen PTEN VCEP specification v3.2, BP6 entry: applicability is Not Applicable for this VCEP.
Sources
BP7 N/ANot applicable: PTEN BP7 requires a synonymous or intronic variant at or beyond +7/-21, but c.147del is a coding frameshift variant. Details ▾Hide ▴
Reasoning

The PTEN VCEP BP7 rule applies to synonymous (silent) or intronic variants at or beyond +7/-21 with splice prediction algorithms showing no impact. NM_000314.8:c.147del is a coding frameshift variant, p.(Asn49LysfsTer5), not synonymous or intronic and not within BP7's named location scope.

VCEP rule
A synonymous (silent) or intronic variant at or beyond +7/-21 for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice.
Evidence considered
  • ClinGen PTEN VCEP BP7 rule: ‘A synonymous (silent) or intronic variant at or beyond +7/-21 for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice.’
  • Variant NM_000314.8:c.147del is a coding frameshift producing NP_000305.3:p.(Asn49LysfsTer5), so it is neither synonymous nor intronic and BP7 is outside scope.
Sources

Identifiers

Gene
PTEN
Transcript
NM_000314.8
Coding (HGVS c.)
NM_000314.8:c.147del
Protein (HGVS p.)
NP_000305.3:p.(Asn49LysfsTer5)
GRCh38
chr10:87894091 AT>A
GRCh37
chr10:89653848 AT>A
Location and type
Exon 2 · frameshift
ClinVar
2682058

Gene diagram

Every interpreted variant in PTEN, mapped onto the exon structure of NM_000314.8. Select a row to find it on the plot.

PTENNM_000314.8
Fetching transcript structure from UCSC…
gnomAD v4.1 Allele count data not recorded
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

Statements

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -73 bp
0.287
SpliceAI acceptor gainat +18 bp
0.000
SpliceAI donor lossat +18 bp
0.174
SpliceAI donor gainat -27 bp
0.000
Pangolin splice lossmagnitude shown
-0.213
Pangolin splice gain
0.032

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

PP3 N/ANot applicable: PTEN PP3 covers synonymous/intronic splice predictions or missense REVEL >0.7, whereas c.147del is a frameshift variant. Details ▾Hide ▴
Reasoning

The PTEN VCEP PP3 rule scopes the splicing pathway to synonymous or intronic variants and the protein-impact pathway to missense variants with REVEL score > 0.7. NM_000314.8:c.147del is a frameshift variant, p.(Asn49LysfsTer5), so it lies outside every PP3 pathway. The available SpliceAI result is not used because the governing PP3 rule does not name frameshift variants as an applicable situation.

VCEP rule
To be applied to synonymous or intronic variants where SpliceAl and VarSeak _in silico_ models predict a splicing impact (SpliceAl: scores 0.5-1 are consider evidence of pathogenic. VarSeak: Class 4 and 5 are consider evidence of pathogenic). May also be applied to missense variants with REVEL score > 0.7.
Evidence considered
  • ClinGen PTEN VCEP PP3 specification: ‘To be applied to synonymous or intronic variants where SpliceAl and VarSeak _in silico_ models predict a splicing impact (SpliceAl: scores 0.5-1 are consider evidence of pathogenic. VarSeak: Class 4 and 5 are consider evidence of pathogenic). May also be applied to missense variants with REVEL score > 0.7.’
  • Variant NM_000314.8:c.147del produces NP_000305.3:p.(Asn49LysfsTer5) and is classified in the case facts as a frameshift, not a synonymous, intronic, or missense variant; therefore no PP3 pathway applies.
Sources
BP4 N/ANot applicable: PTEN BP4 covers synonymous/intronic splice predictions or missense REVEL <0.5, while c.147del is a frameshift with a truncating protein effect. Details ▾Hide ▴
Reasoning

The PTEN VCEP BP4 rule scopes the splicing pathway to synonymous or intronic variants with concordant SpliceAl and VarSeak predictions of no splicing impact, and separately allows missense variants with REVEL score < 0.5. NM_000314.8:c.147del is a frameshift variant, p.(Asn49LysfsTer5), outside both pathways. BP4 is therefore not applicable; a no-impact splice prediction cannot negate the truncating protein effect.

VCEP rule
To be applied to synonymous or intronic variants where SpliceAl and VarSeak _in silico_ models predict no splicing impact (SpliceAl: scores 0-0.2 are considered evidence of benign. VarSeak: Class 1 and 2 are considered evidence of benign). Not to be applied for variants which may impact the intron 1 splice donor or acceptor sites, and to be used cautiously for variants which may impact the intron 6 splice acceptor. May also be applied to missense variants with REVEL score \< 0.5.
Evidence considered
  • ClinGen PTEN VCEP BP4 specification: ‘To be applied to synonymous or intronic variants where SpliceAl and VarSeak _in silico_ models predict no splicing impact (SpliceAl: scores 0-0.2 are considered evidence of benign. VarSeak: Class 1 and 2 are considered evidence of benign). Not to be applied for variants which may impact the intron 1 splice donor or acceptor sites, and to be used cautiously for variants which may impact the intron 6 splice acceptor. May also be applied to missense variants with REVEL score < 0.5.’
  • Variant NM_000314.8:c.147del produces NP_000305.3:p.(Asn49LysfsTer5) and is classified in the case facts as a frameshift, outside the synonymous/intronic and missense BP4 pathways; any SpliceAI result is not evidence for BP4 in this situation.
Sources
BP7 N/ANot applicable: PTEN BP7 requires a synonymous or intronic variant at or beyond +7/-21, but c.147del is a coding frameshift variant. Details ▾Hide ▴
Reasoning

The PTEN VCEP BP7 rule applies to synonymous (silent) or intronic variants at or beyond +7/-21 with splice prediction algorithms showing no impact. NM_000314.8:c.147del is a coding frameshift variant, p.(Asn49LysfsTer5), not synonymous or intronic and not within BP7's named location scope.

VCEP rule
A synonymous (silent) or intronic variant at or beyond +7/-21 for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice.
Evidence considered
  • ClinGen PTEN VCEP BP7 rule: ‘A synonymous (silent) or intronic variant at or beyond +7/-21 for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice.’
  • Variant NM_000314.8:c.147del is a coding frameshift producing NP_000305.3:p.(Asn49LysfsTer5), so it is neither synonymous nor intronic and BP7 is outside scope.
Sources

Statement

In silico

SpliceAI predicts possible splice impact for this variant (max delta score = 0.29).

3 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • PTEN: life as a tumor suppressor.
    No paper-specific finding is recorded.
    PMID 11237521 ↗
  • Essential role for nuclear PTEN in maintaining chromosomal integrity.
    No paper-specific finding is recorded.
    PMID 17218262 ↗
  • A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.
    Karbassi I et al. · 2016
    The paper does not explicitly mention PTEN c.147del / NP_000305.3:p.(N49Kfs*5), nor does the provided text report PTEN-specific case observations, phenotype data, segregation data, or population frequency for this variant.
    Does not name this variant
    PMID 26467025 ↗
    Quoted passage
    A special consideration was given to genes where null variants (e.g., frameshift, nonsense, canonical splice site variants at the ±1,2 positions associated with out-of-frame events) were documented in the literature to cause well-characterized disease phenotypes.

    Materials and Methods, A Rules-Based, Weighted Variant Scoring System

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

ClinVar

Error retrieving ClinVar entry.

In silico

SpliceAI predicts possible splice impact for this variant (max delta score = 0.29).

Functional

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.